ALK and non-small cell lung carcinoma: Moreover, promising results have been obtained with the HSP90 inhibitor, such as NVP-AUY922/Luminespib (Novartis) which is currently tested in EML4-ALK(+) NSCLC patients as a single agent or in combination with the ALK inhibitor LDK378 (NCT01124864, NTC01752400, NTC01772797).